Aldodetect Medtech Co. Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Development of a multiplex biomarker test kit for primary aldosteronism (PA) (which detects a combination of specific protein biomarkers in a patient’s blood and can be used in hospitals or testing centers via mainstream automated immunoassay platforms such as enzyme-linked immunosorbent assay (ELISA), utilizing an artificial intelligence-based multimodal fusion architecture and a multi-level interpretability decision model, the algorithm processes the patient’s clinical data (such as age, blood pressure, and serum potassium), biochemical indicators (such as aldosterone concentration, renin activity, and electrolytes), corticosteroid data, and the aforementioned protein biomarkers into the algorithm, the test can be completed within a few hours.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60488228
Status
Active
Number of Employees
0
Total Paid-in
Capital
28,200,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Aldodetect Medtech is committed to clinical innovation in precision medicine, with a focus on screening and diagnostic methods for resistant hypertension. The company’s advanced multi-omics testing technology and AI-powered diagnostic model analysis platform provide more accurate and efficient testing solutions for the hundreds of millions of patients with resistant hypertension.
The content above was translated by Ai
